Sound Bioventures

Sound Bioventures is a venture capital firm investing in early-stage life sciences companies developing novel therapeutics for unmet medical needs. The firm focuses on private companies in Europe and the United States that are about to enter the clinical stage of drug development. Sound Bioventures aims to support the advancement of innovative medicines addressing significant clinical needs.

The firm's investment strategy emphasizes an active, hands-on approach, with the founding team bringing considerable operational and venture capital investment experience. They invest in companies where private investors can finance the research and development program all the way to regulatory approval. Sound Bioventures operates from key locations in Copenhagen, Stockholm, and Washington D.C., reflecting its commitment to both Scandinavian and international biotech ecosystems.

Sound Bioventures has a track record of supporting companies in various therapeutic areas. For instance, in June 2024, the firm invested in NephroDI Therapeutics, a U.S.-based company developing treatments for pediatric kidney diseases. In April 2024, Sound Bioventures participated in a £19 million financing round for Theolytics, a UK biotechnology company focused on oncolytic viral therapies. These investments demonstrate the firm's dedication to advancing innovative treatments for unmet medical needs across different regions and therapeutic areas.